CEO
Nava Therapeutics, United States
Federico Mingozzi is the Chief Executive Officer of a startup biotechnology company developing genome medicines. His career journey in gene therapy and immunology began in 2000 as a scientist in Philadelphia, working at the Children’s Hospital of Philadelphia and the University of Pennsylvania. Following this, he moved to France to take on the role of an independent investigator at the French National Institute of Health and Medical Research (INSERM) and the R&D institute Genethon. In 2017, he returned to Philadelphia, joining Spark Therapeutics as the Chief Scientific Officer.
Federico serves as the treasurer and a board member of the American Society of Gene and Cell Therapy (ASGCT). He is also a member of scientific advisory boards for non-profit organizations and biotech companies. In the past, he was a faculty member at Pierre and Marie Curie University in Paris, France, and the Universitat Autonoma of Barcelona, Spain. His educational background includes a bachelor’s degree in biology and a Ph.D. in biochemistry and molecular biology from the University of Ferrara in Italy. He also completed an M.B.A. at Drexel University.
Disclosure information not submitted.
Human Immune Responses to Viral Gene Therapy Vectors
Wednesday, June 19, 2024
1:00 PM - 1:25 PM PT
